To compare the effectiveness of Interleukin (IL)-12/23 or IL-17A inhibitors (summarized to inhibitors of the Th17 cell generation or function, Th17i) with tumor necrosis factor inhibitors (TNFi) in patients with TNFi-experienced psoriatic arthritis (PsA). Here, TNF is linked to psoriatic arthritis.